Private company

Longboard Pharmaceuticals, Inc.

In its 2024 annual report the company says: “We are a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Our small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of world-class GPCR research.”3 It is headquartered in La Jolla, California.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersLa Jolla, California1
  • Business address4275 Executive Square, Suite 950, La Jolla, Ca 920372
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. We were formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Our small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of world-class GPCR research. Arena was purchased by Pfizer, Inc. (Pfizer) on March 11, 2022 and is now a wholly-owned subsidiary of Pfizer.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456-$56.8M in 2023+294% since 2020
-$60.0M-$40.0M-$20.0M02020: -$14.4M-$14.4M20202021: -$27.8M-$27.8M2021+93%2022: -$44.8M-$44.8M2022+61%2023: -$56.8M-$56.8M2023+27%
Net income456-$54.4M in 2023+278% since 2020
-$60.0M-$40.0M-$20.0M02020: -$14.4M-$14.4M20202021: -$27.8M-$27.8M2021+93%2022: -$43.9M-$43.9M2022+58%2023: -$54.4M-$54.4M2023+24%
Fiscal year20202021202220232024
Research and development$4.6M4$19.8M5$34.6M6$43.8M6
Operating expenses$27.8M5$44.8M6$56.8M6
Operating income-$14.4M4-$27.8M5-$44.8M6-$56.8M6
Income tax$04$05$06$06
Net income-$14.4M4-$27.8M5-$43.9M6-$54.4M6
Earnings per share-$1.935-$2.566-$2.396
Earnings per share (diluted)-$1.935-$2.566-$2.396
Shares (weighted, basic)14.4M shares517.2M shares622.7M shares6
Shares (weighted, diluted)14.4M shares517.2M shares622.7M shares6

Compare Longboard Pharmaceuticals, Inc. with another company

Corporate structure

Longboard Pharmaceuticals, Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Longboard Pharmaceuticals, Inc.

  • RA CAPITAL MANAGEMENT, L.P. Filed SCHEDULE 13G/A on Longboard Pharmaceuticals, Inc., latest Feb 14, 2025 (2 filings since Jan 12, 2024)
  • VIKING GLOBAL INVESTORS LP Filed SCHEDULE 13G/A on Longboard Pharmaceuticals, Inc., latest Feb 14, 2025 (2 filings since Jul 15, 2024)
  • Zone II Healthcare Holdings, LLC Filed SCHEDULE 13G/A on Longboard Pharmaceuticals, Inc., latest Feb 11, 2025
  • Cormorant Asset Management, LP Filed SC 13G/A on Longboard Pharmaceuticals, Inc., latest Nov 14, 2024 (4 filings since Feb 14, 2022)
  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on Longboard Pharmaceuticals, Inc., latest Nov 14, 2024 (4 filings since Feb 14, 2022)
  • VANGUARD GROUP INC Filed SC 13G/A on Longboard Pharmaceuticals, Inc., latest Nov 12, 2024 (2 filings since Nov 4, 2024)
  • BlackRock Filed SC 13G on Longboard Pharmaceuticals, Inc., latest Nov 8, 2024 (2 filings since Oct 22, 2024)
  • Farallon Capital Partners, L.P. Filed SC 13G/A on Longboard Pharmaceuticals, Inc., latest Nov 8, 2024 (3 filings since Feb 3, 2023)
  • FMR LLC Filed SC 13G/A on Longboard Pharmaceuticals, Inc., latest Nov 7, 2024 (8 filings since Feb 9, 2022)
  • Point72 Asset Management, L.P. Filed SC 13G/A on Longboard Pharmaceuticals, Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • HBM Healthcare Investments (Cayman) Ltd. Filed SC 13G/A on Longboard Pharmaceuticals, Inc., latest Feb 13, 2024 (2 filings since Feb 14, 2023)
  • Prosight Management, LP Filed SC 13G/A on Longboard Pharmaceuticals, Inc., latest Feb 13, 2024 (2 filings since Apr 20, 2023)
  • Longboard Pharmaceuticals, Inc. La Jolla, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Longboard Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$4.0K6 Dec 31, 2023$9.0K6 Dec 31, 2022−55.6%
Operating-lease assets (leased space)$472.0K6 Dec 31, 2023$736.0K6 Dec 31, 2022−35.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$14.3M6 Dec 31, 2023$10.8M6 Dec 31, 2022+33.0%
Marketable securities, current$34.2M6 Dec 31, 2023$56.8M6 Dec 31, 2022−39.9%
Debt securities available for sale$34.2M6 Dec 31, 2023$56.8M6 Dec 31, 2022−39.9%

Leadership

Who has led Longboard Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Kevin Robert Lind2021–2024

President

  1. Kevin Robert Lind2021–2024

Chief financial officer

  1. Brandi Roberts2021–2024
2025
Board members and other officers (9)

Timeline

  1. Dec 2, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer19
  2. Nov 7, 20248-K Results of operations20
  3. Oct 15, 20248-K Entered a material agreement; Executive or director change; Regulation FD disclosure21
  4. Aug 1, 20248-K Results of operations; Regulation FD disclosure; Other events22
  5. Jul 1, 20248-K Regulation FD disclosure; Other events23
  6. Jun 10, 20248-K Regulation FD disclosure; Other events24
  7. May 24, 20248-K Change to shareholders' rights; Executive or director change; Shareholder vote25
  8. May 2, 20248-K Results of operations26
  9. Apr 15, 20248-K Regulation FD disclosure27
  10. Mar 26, 20248-K Unregistered sale of shares28
  11. Mar 12, 20248-K Results of operations; Regulation FD disclosure29
  12. Jan 4, 20248-K Other events30
  13. Mar 11, 2021New chief executive Kevin Robert Lind becomes CEO9

Calendar

When it reported results

  1. Nov 7, 2024Reported quarterly or annual results20
  2. Aug 1, 2024Reported quarterly or annual results22
  3. May 2, 2024Reported quarterly or annual results26
  4. Mar 12, 2024Reported quarterly or annual results29
  5. Jan 2, 2024Reported quarterly or annual results31
  6. Nov 2, 2023Reported quarterly or annual results32
  7. Aug 3, 2023Reported quarterly or annual results33
  8. May 9, 2023Reported quarterly or annual results34

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

200 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 38 major events, 48 insider forms, 43 large holders, 58 other. The latest 20:

  1. Feb 14, 2025SCHEDULE 13G/A EDGAR
  2. Feb 14, 2025SCHEDULE 13G/A EDGAR
  3. Feb 11, 2025SCHEDULE 13G/A EDGAR
  4. Dec 12, 202415-12G EDGAR
  5. Dec 10, 2024POSASR EDGAR
  6. Dec 10, 2024RW WD EDGAR
  7. Dec 9, 2024EFFECT EDGAR
  8. Dec 9, 2024EFFECT EDGAR
  9. Dec 9, 2024EFFECT EDGAR
  10. Dec 2, 20244 EDGAR
  11. Dec 2, 20244 EDGAR
  12. Dec 2, 20244 EDGAR
  13. Dec 2, 20244 EDGAR
  14. Dec 2, 20244 EDGAR
  15. Dec 2, 20244 EDGAR
  16. Dec 2, 20244 EDGAR
  17. Dec 2, 20244 EDGAR
  18. Dec 2, 2024RW EDGAR
  19. Dec 2, 2024S-8 POS EDGAR
  20. Dec 2, 2024S-8 POS EDGAR

The 200 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 1 buys and 5 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 15, 2024Kaye RandallExecutive Vice President & CMOSale16,667$59.04$984.0KForm 4
Sep 16, 2024Kaye RandallExecutive Vice President & CMOSale16,666$31.64$527.3KForm 4
Aug 12, 2024Kaye RandallExecutive Vice President & CMOSale16,667$34.73$578.8KForm 4
Jun 25, 2024Kaye RandallExecutive Vice President & CMOSale100$20.87$2.1KForm 4
Jan 25, 2024ARENA PHARMACEUTICALS INCSale3,978,540$24.25$96.5MForm 4
Jan 23, 2024Kaye RandallExecutive Vice President & CMOBuy100$24.82$2.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Longboard Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLongboard Pharmaceuticals, Inc.1
  • CIK0001832168
  • Employer ID (EIN)84-50096191
  • Filer status<br>emerging growth company1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4275 Executive Square, Suite 950, La Jolla, CA 920371
  • Phone619-592-97751
  • Shares outstanding39,045,703 as of Nov 5, 20248
  • Public float$148.3M as of Jun 30, 20236
  • On EDGAR sinceNov 18, 20201
  • Filings244 in all: 4 (50), 8-K (41), SC 13G/A (28), SC 13G (13), 10-Q (12), 3 (11), CORRESP (6), EFFECT (6)1
    All 47 form types

    424B5 (5), S-8 (4), S-8 POS (4), SC TO-C (4), SC TO-T/A (4), UPLOAD (4), 10-K (3), DEF 14A (3), DEFA14A (3), POS AM (3), SC 13D/A (3), SC 14D9/A (3), SCHEDULE 13G/A (3), 144 (2), ARS (2), S-3 (2), SC14D9C (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), 8-A12B/A (1), CERT (1), D (1), DRS (1), DRS/A (1), DRSLTR (1), POSASR (1), PRE 14A (1), RW (1), RW WD (1), S-1 (1), S-1/A (1), S-3ASR (1), S-3MEF (1), SC 13D (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 12, 2024
    Quarterly report (10-Q) Nov 7, 2024
    Proxy statement (DEF 14A) Apr 12, 2024
    Latest 8-K (8-K) Dec 2, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50